Bambusa Therapeutics Marks Milestone with First Patient Dosed in COPD Study of BBT002 Bambusa Therapeutics has begun dosing patients in a Phase Ib study of BBT002, focusing on chronic obstructive pulmonary disease and type 2 inflammation.

Bambusa Therapeutics Marks Milestone with First Patient Dosed in COPD Study of BBT002 #USA #Boston #COPD #Bambusa_Therapeutics #BBT002

Bambusa Therapeutics Begins Phase 1 Trial for Innovative Bispecific Antibody BBT002 Bambusa Therapeutics has initiated a Phase 1 clinical trial for BBT002, a groundbreaking bispecific antibody targeting various inflammatory conditions, demonstrating impressive preclinical results.

Bambusa Therapeutics Begins Phase 1 Trial for Innovative Bispecific Antibody BBT002 #United_States #Boston #Clinical_Trial #Bambusa_Therapeutics #BBT002